Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer
Author
Sevinç, A.
Yannoukakos, D.
Konstantopoulou, I.
Manguoglu, E.
Lüleci, G.
Çolak, T.
Akyerli, C.
Çolakoglu, G.
Tez, M.
Sayek, I.
Gerassimos, V.
Nasioulas, G.
Papadopoulou, E.
Florentin, L.
Kontogianni, E.
Bozkurt, B.
Kocabas, N. A.
Karakaya, A. E.
Yulug, I. G.
Özçelik, T.
Date
2004Source Title
Anticancer Research
Print ISSN
0250-7005
Publisher
International Institute of Anticancer Research
Volume
24
Issue
4
Pages
2547 - 2549
Language
English
Type
ArticleItem Usage Stats
78
views
views
16
downloads
downloads
Abstract
Background: The RNASEL G1385A variant was recently found to be implicated in the development of prostate cancer. Considering the function of RNase L and the pleiotropic effects of mutations associated with cancer, we sought to investigate whether the RNASEL G1385A variant is a risk factor for breast cancer. Patients and Methods: A total of 453 breast cancer patients and 382 age- and sex-matched controls from Greece and Turkey were analyzed. Genotyping for the RNASEL G1385A variant was performed using an Amplification Refractory Mutation System (ARMS). Results: Statistical evaluation of the RNASEL G1385A genotype distribution among breast cancer patients and controls revealed no significant association between the presence of the risk genotype and the occurrence of breast cancer. Conclusion: Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk, this variant does not appear to be implicated in the development of breast cancer.
Keywords
Breast cancerRNASEL
Arginine
Glutamine
Ribonuclease L
Adolescent
Aged
Amino acid sequence
Amplification refractory mutation system
Article
Breast cancer
Cancer risk
Controlled study
Disease association
Female
Gene amplification
Gene mutation
Genotype
Greece
Human
Human tissue
Major clinical study
Pleiotropy
Priority journal
Protein variant
Risk factor
Turkey (republic)
Adult
Aged
Aged, 80 and over
Alleles
Breast Neoplasms
Case-Control Studies
DNA, Neoplasm
Endoribonucleases
Female
Humans
Middle aged
Mutation
Risk factors